MARKET

ATOS

ATOS

Atossa Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.990
-0.910
-23.33%
After Hours: 3.040 +0.05 +1.67% 19:58 07/30 EDT
OPEN
3.701
PREV CLOSE
3.900
HIGH
3.720
LOW
2.800
VOLUME
41.29M
TURNOVER
--
52 WEEK HIGH
9.80
52 WEEK LOW
0.8100
MARKET CAP
361.26M
P/E (TTM)
-1.9636
1D
5D
1M
3M
1Y
5Y
Flora Growth leads weekly healthcare gainers; Alzheimer’s-focused stocks trail
After four back-to-back sessions of gains, the healthcare stocks in the S&P 500 finished ~0.5% higher this week to outperform the ~0.4% loss recorded by the broader index over the past five-day period. A
Seekingalpha · 3h ago
ATOS Stock: The Big News That Has Atossa Therapeutics Plunging 20% Today
Investor Place · 1d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers
Benzinga · 1d ago
MRIN, BLIN, BAP among mid-day movers
Gainers: ERYTECH Pharma ERYP +64%. Allied Healthcare Products AHPI +49%. iFresh (NASDAQ:IFMK) +35%. Marin Software Incorporated (NASDAQ:MRIN) +29%. Atlassian Corporation TEAM +24%. Xiaobai Maimai (NASDAQ:HX) +18%. First High-School Education (NYSE:FHS) +16...
Seekingalpha · 1d ago
Atossa Therapeutics Seeks Shareholder Approval to Expand Authorized Common Shares -- Shares Plunge
MT Newswires · 1d ago
ERYTECH Pharma, Allied Healthcare Products leads healthcare gainers; Intec Pharma, Translate Bio among major losers
Gainers: ERYTECH Pharma (NASDAQ:ERYP) +84%, Allied Healthcare Products (NASDAQ:AHPI) +31%, SCWorx (NASDAQ:WORX) +18%, Veracyte (NASDAQ:VCYT) +13%, Misonix (NASDAQ:MSON) +11%. Losers: Intec Pharma (NASDAQ:NTEC) -20%, Translate Bio (NASDAQ:TBIO) -17%, ATI Ph...
Seekingalpha · 1d ago
Atossa loses a tenth after convening a special meeting for shareholders
Atossa Therapeutics (ATOS -13.2%) has lost more than a tenth in value in morning hours after the company announced a special meeting of stockholders seeking approval for an amendment to the
Seekingalpha · 1d ago
Understanding Atossa Therapeutics's Unusual Options Activity
Atossa Therapeutics (NASDAQ:ATOS) shares experienced unusual options activity on Thursday. The stock price moved up to $4.08 following the option alert.
Benzinga · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATOS. Analyze the recent business situations of Atossa Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATOS stock price target is 7.50 with a high estimate of 8.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 55
Institutional Holdings: 10.81M
% Owned: 8.95%
Shares Outstanding: 120.82M
TypeInstitutionsShares
Increased
11
7.89M
New
36
1.41M
Decreased
3
71.24K
Sold Out
3
900
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.07%
Pharmaceuticals & Medical Research
-0.24%
Key Executives
Chairman/Chief Executive Officer/President/Director
Steven Quay
Chief Financial Officer/General Counsel/Secretary
Kyle Guse
Director
Shu-Chih Chen
Independent Director
Stephen Galli
Independent Director
H. Lawrence Remmel
Independent Director
Richard Steinhart
Independent Director
Gregory Weaver
No Data
  • All
  • Financials
  • Insiders
More
About ATOS
Atossa Therapeutics Inc., formerly Atossa Genetics Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics and delivery methods for breast cancer and other breast conditions. Its pipeline includes two programs: endoxifen and intraductal microcatheter technology. It is developing Topical Endoxifen formulation for transdermal delivery. It is developing Topical Endoxifen to address two populations: to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy. It is also developing oral presentation of endoxifen. It is developing its microcatheter technology to deliver therapeutics through the nipple directly to the site of early breast cancer. It is also developing our proprietary intraductal microcatheter technology for Chimeric Antigen Receptor Therapy (CAR-T).

Webull offers kinds of Atossa Therapeutics Inc stock information, including NASDAQ:ATOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATOS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATOS stock methods without spending real money on the virtual paper trading platform.